<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2250">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00401518</url>
  </required_header>
  <id_info>
    <org_study_id>1020-9052</org_study_id>
    <nct_id>NCT00401518</nct_id>
  </id_info>
  <brief_title>A Pivotal Study of a Facet Replacement System to Treat Spinal Stenosis</brief_title>
  <official_title>The Investigational Plan for the Evaluation of the ACADIA® Facet Replacement System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Globus Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Globus Medical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the ACADIA® Facet Replacement System is&#xD;
      effective in the treatment of spinal stenosis. The primary objective of the study is to&#xD;
      evaluate the overall success rate of the Anatomic Facet Replacement System in patients with&#xD;
      spinal stenosis when compared to a posterior spinal fusion control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinal Stenosis continues to be a major cause of back and leg pain. The condition is&#xD;
      attributed to narrowing of the space around the nerves in the lumbar spine. This is often&#xD;
      caused by the degenerative process in the spine and the facet joints. The current treatment&#xD;
      calls for removal of bone around the affected nerve including the facet joints and fusing the&#xD;
      posterior of the spine to ensure the segments remain stable.&#xD;
&#xD;
      The ACADIA® Facet Replacement System (AFRS) allows for an anatomic reconstruction of the&#xD;
      facet joint after decompression and removal of the degenerated facet. Like the original facet&#xD;
      joint, the replacement implant is designed to reproduce facet motion while restoring normal&#xD;
      stability and motion.&#xD;
&#xD;
      The ACADIA® Facet Replacement System (AFRS) has been designed on the principals that have&#xD;
      allowed other total joint replacement procedures to provide significant patient benefits.&#xD;
      These guiding principals include:&#xD;
&#xD;
        -  Anatomically based implant design&#xD;
&#xD;
        -  Reproducible surgical technique&#xD;
&#xD;
        -  Elimination of pain&#xD;
&#xD;
      The ACADIA® Facet Replacement System allows the surgeon to remove the offending bone while&#xD;
      preserving the motion of the facet joint.&#xD;
&#xD;
      This study will evaluate the outcomes of patients using the AFRS™ investigation compared to&#xD;
      those receiving instrumented posterior fusion procedure. Patients will be required to&#xD;
      complete study visits before the procedure and at 6 weeks, 3, 6, 12, 24 months post procedure&#xD;
      and annually thereafter as required by FDA. Follow up visits consist of administration of&#xD;
      questionnaires, radiographs and neurological assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Physical Function Score</measure>
    <time_frame>24 months</time_frame>
    <description>Physical Function is measured on a scale of 1-4 points (lower values are considered a better outcome)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Symptom Severity Score</measure>
    <time_frame>24 months</time_frame>
    <description>Symptom Severity is measured on a scale of 1-5 points (lower values are considered a better outcome)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Maintained or Improved in Neurological Status.</measure>
    <time_frame>24 months</time_frame>
    <description>Neurological status is based on four types of measurement parameters: muscle strength, straight leg raise, sensory function, and reflexes. Each of the four parameters will be coded as Stable or Improved OR Deteriorated. Neurological assessment scores must be stable or improved compared with the preoperative baseline to be considered &quot;Stable or Improved&quot; neurological status. If these scores have deteriorated as compared to the preoperative baseline, then the neurological status is considered &quot;Deteriorated&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Visual Analog Scale (VAS) Right Leg Pain</measure>
    <time_frame>24 months</time_frame>
    <description>The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with &quot;no pain&quot; on the left border and &quot;as severe as it could be&quot; on the right border. The subject is instructed to make a mark along the line to represent the intensity of right leg pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Visual Analog Scale (VAS) Left Leg Pain</measure>
    <time_frame>24 months</time_frame>
    <description>The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with &quot;no pain&quot; on the left border and &quot;as severe as it could be&quot; on the right border. The subject is instructed to make a mark along the line to represent the intensity of left leg pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Visual Analog Scale (VAS) Back Pain</measure>
    <time_frame>24 months</time_frame>
    <description>The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with &quot;no pain&quot; on the left border and &quot;as severe as it could be&quot; on the right border. The subject is instructed to make a mark along the line to represent the intensity of back pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Change of at Least 15 Points in Pain/Disability Using the Oswestry Disability Index (ODI) Score at 24 Months Compared With the Score at Baseline</measure>
    <time_frame>24 months</time_frame>
    <description>The Oswestry Disability Index (ODI) is a commonly used outcome-measure questionnaire for low back pain in a hospital setting. It is a self-administered questionnaire divided into ten sections designed to assess limitations of various activities of daily living. Each section is scored on a 0-5 scale, 5 representing the greatest disability. The scores for all questions answered are summed, then multiplied by two to obtain the index (range 0 to 100). Zero is equated with no disability and 100 is the maximum disability possible.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">390</enrollment>
  <condition>Lumbar Spinal Stenosis</condition>
  <arm_group>
    <arm_group_label>ACADIA®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational surgical treatment using the ACADIA Facet Replacement system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Instrumented PLF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control surgical treatment using an instrumented posterolateral fusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-randomized ACADIA® Facet Replacement System</intervention_name>
    <description>Non-randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis</description>
    <arm_group_label>ACADIA®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Randomized ACADIA® Facet Replacement System</intervention_name>
    <description>Randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis</description>
    <arm_group_label>ACADIA®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Randomized Instrumented posterolateral fusion (PLF)</intervention_name>
    <description>Randomized control treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis</description>
    <arm_group_label>Control Instrumented PLF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  21-85 years of age and skeletally mature;&#xD;
&#xD;
          -  Have undergone 6 months of non-operative treatment prior to surgery;&#xD;
&#xD;
          -  Lateral, lateral recess and/or central canal stenosis;&#xD;
&#xD;
          -  Disc height measuring ≥ 4 mm at the operative level;&#xD;
&#xD;
          -  Persistent leg, thigh and/or buttock symptoms,including pain,numbness, burning or&#xD;
             tingling with a minimum leg pain score of 40mm as measured with the Visual Analogue&#xD;
             Scale (VAS) Index;&#xD;
&#xD;
          -  A score greater than 2 on a scale of 1-5 on the Zurich Claudication Questionnaire&#xD;
             (ZCQ) Symptom Severity (SS) Score-Candidate;&#xD;
&#xD;
          -  A score greater than or equal to 2 on a scale of 1-4 on the ZCQ Physical Function (PF)&#xD;
             Score;&#xD;
&#xD;
          -  A candidate for a decompression with full facetectomy at the operative level&#xD;
&#xD;
          -  Candidate for a posterior lumbar fusion;&#xD;
&#xD;
          -  Physically and mentally willing and able to comply evaluations;&#xD;
&#xD;
          -  Lives in the immediate area and has no plans to relocate;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous surgical procedure at the operative or adjacent level except for one of the&#xD;
             following: Micro-discectomy, laminectomy, lamino/foraminotomy, rhizotomy, IDET, and/or&#xD;
             interspinous spacer;&#xD;
&#xD;
          -  Previous lumbar fusion or disc replacement procedure;&#xD;
&#xD;
          -  Osteoporosis;&#xD;
&#xD;
          -  greater than Grade I spondylolisthesis or retrolisthesis;&#xD;
&#xD;
          -  Spondylolisthesis at levels other than at the operative level;&#xD;
&#xD;
          -  Scoliosis of the lumbar spine (defined as more than 11 deg Cobb angle) as indicated by&#xD;
             plain X-ray films;&#xD;
&#xD;
          -  Primary diagnosis of discogenic back pain due to torn, herniated, inflamed or&#xD;
             irritated disc or other pathology where the patient exhibits axial back pain from&#xD;
             degenerative disc disease;&#xD;
&#xD;
          -  Acute traumatic pars fracture at the operative/adjacent level vertebral body;&#xD;
&#xD;
          -  Spinal stenosis at more than three lumbar segments;&#xD;
&#xD;
          -  Acute trauma to the lumbar spine within the last 24 months;&#xD;
&#xD;
          -  Active infection at the operative level, or a systemic infection;&#xD;
&#xD;
          -  Physically / mentally compromised;&#xD;
&#xD;
          -  Systemic disease that would affect the patient's welfare or the research study.&#xD;
&#xD;
          -  Immunologically suppressed or immunocompromised;&#xD;
&#xD;
          -  Insulin-Dependent Diabetes Mellitus (Type I Diabetes);&#xD;
&#xD;
          -  Currently undergoing long-term steroid therapy;&#xD;
&#xD;
          -  Metabolic bone disease;&#xD;
&#xD;
          -  Active malignancy: (except non-melanoma skin cancer), unless treated with no clinical&#xD;
             signs or symptoms of the malignancy for at least 5 years;&#xD;
&#xD;
          -  Known allergy to cobalt chromium or titanium;&#xD;
&#xD;
          -  Used any investigational drug or device within the past 30 days;&#xD;
&#xD;
          -  Pending litigation related to back pain or injury;&#xD;
&#xD;
          -  Is a prisoner.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Spine Group Beverly Hills</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Spine Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Orthopaedic Center</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boulder Neurosurgical &amp; Spine Associates</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spine Colorado</name>
      <address>
        <city>Durango</city>
        <state>Colorado</state>
        <zip>81301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Associates (RMA) in Orthopedic Medicine</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Spine Institute</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foundation for Orthopaedic Research and Education</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Institute of Savannah and Center for Spine</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Spine Group</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Orthopaedics</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spine Institute of Louisiana</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rubin Institute for Advanced Orthopaedics</name>
      <address>
        <city>Owings Mills</city>
        <state>Maryland</state>
        <zip>21117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMASS Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spine Midwest, Inc.</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Neurological &amp; Spine Institute</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Neurosurgery and Spine Associates, P.C.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrthoCarolina Spine Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverhills Healthcare</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Brain &amp; Spine</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Spine Solutions</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Sports Medicine &amp; Orthopedics</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Spine Institute</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 17, 2006</study_first_submitted>
  <study_first_submitted_qc>November 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2006</study_first_posted>
  <results_first_submitted>August 10, 2020</results_first_submitted>
  <results_first_submitted_qc>August 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2020</results_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal Stenosis</keyword>
  <keyword>Lumbar Spinal Stenosis</keyword>
  <keyword>Facet Arthroplasty</keyword>
  <keyword>Posterior Fusion</keyword>
  <keyword>Facet Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 14, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT00401518/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Non-randomized ACADIA®</title>
          <description>Non-randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
        </group>
        <group group_id="P2">
          <title>Randomized ACADIA®</title>
          <description>Randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
        </group>
        <group group_id="P3">
          <title>Randomized Instrumented PLF</title>
          <description>Randomized control surgical treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="227"/>
                <participants group_id="P3" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="190"/>
                <participants group_id="P3" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Non-randomized ACADIA®</title>
          <description>Non-randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
        </group>
        <group group_id="B2">
          <title>Randomized ACADIA®</title>
          <description>Randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
        </group>
        <group group_id="B3">
          <title>Randomized Instrumented PLF</title>
          <description>Randomized control surgical treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="227"/>
            <count group_id="B3" value="117"/>
            <count group_id="B4" value="390"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="11.46"/>
                    <measurement group_id="B2" value="61.7" spread="9.82"/>
                    <measurement group_id="B3" value="61.4" spread="10.55"/>
                    <measurement group_id="B4" value="61.2" spread="10.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="196"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian or Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="3.91"/>
                    <measurement group_id="B2" value="66.9" spread="4.41"/>
                    <measurement group_id="B3" value="67.4" spread="3.86"/>
                    <measurement group_id="B4" value="67.1" spread="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190.8" spread="41.34"/>
                    <measurement group_id="B2" value="191.3" spread="39.62"/>
                    <measurement group_id="B3" value="191.2" spread="37.38"/>
                    <measurement group_id="B4" value="191.2" spread="39.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measure of Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Physical Function Score</title>
        <description>Physical Function is measured on a scale of 1-4 points (lower values are considered a better outcome)</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-randomized ACADIA®</title>
            <description>Non-randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
          </group>
          <group group_id="O2">
            <title>Randomized ACADIA®</title>
            <description>Randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
          </group>
          <group group_id="O3">
            <title>Randomized Instrumented PLF</title>
            <description>Randomized control surgical treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Physical Function Score</title>
          <description>Physical Function is measured on a scale of 1-4 points (lower values are considered a better outcome)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.71"/>
                    <measurement group_id="O2" value="1.6" spread="0.62"/>
                    <measurement group_id="O3" value="1.7" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measure of Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Symptom Severity Score</title>
        <description>Symptom Severity is measured on a scale of 1-5 points (lower values are considered a better outcome)</description>
        <time_frame>24 months</time_frame>
        <population>One patient from the Randomized ACADIA group did not have ZCQ Symptom Severity data at 24 months</population>
        <group_list>
          <group group_id="O1">
            <title>Non-randomized ACADIA®</title>
            <description>Non-randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
          </group>
          <group group_id="O2">
            <title>Randomized ACADIA®</title>
            <description>Randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
          </group>
          <group group_id="O3">
            <title>Randomized Instrumented PLF</title>
            <description>Randomized control surgical treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Symptom Severity Score</title>
          <description>Symptom Severity is measured on a scale of 1-5 points (lower values are considered a better outcome)</description>
          <population>One patient from the Randomized ACADIA group did not have ZCQ Symptom Severity data at 24 months</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.90"/>
                    <measurement group_id="O2" value="2.0" spread="0.80"/>
                    <measurement group_id="O3" value="2.2" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Maintained or Improved in Neurological Status.</title>
        <description>Neurological status is based on four types of measurement parameters: muscle strength, straight leg raise, sensory function, and reflexes. Each of the four parameters will be coded as Stable or Improved OR Deteriorated. Neurological assessment scores must be stable or improved compared with the preoperative baseline to be considered &quot;Stable or Improved&quot; neurological status. If these scores have deteriorated as compared to the preoperative baseline, then the neurological status is considered &quot;Deteriorated&quot;.</description>
        <time_frame>24 months</time_frame>
        <population>Only patients with Neurological data at 24 months and treated with ACADIA or the control treatment were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Non-randomized ACADIA®</title>
            <description>Non-randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
          </group>
          <group group_id="O2">
            <title>Randomized ACADIA®</title>
            <description>Randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
          </group>
          <group group_id="O3">
            <title>Randomized Instrumented PLF</title>
            <description>Randomized control surgical treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Maintained or Improved in Neurological Status.</title>
          <description>Neurological status is based on four types of measurement parameters: muscle strength, straight leg raise, sensory function, and reflexes. Each of the four parameters will be coded as Stable or Improved OR Deteriorated. Neurological assessment scores must be stable or improved compared with the preoperative baseline to be considered &quot;Stable or Improved&quot; neurological status. If these scores have deteriorated as compared to the preoperative baseline, then the neurological status is considered &quot;Deteriorated&quot;.</description>
          <population>Only patients with Neurological data at 24 months and treated with ACADIA or the control treatment were analyzed</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="155"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Visual Analog Scale (VAS) Right Leg Pain</title>
        <description>The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with &quot;no pain&quot; on the left border and &quot;as severe as it could be&quot; on the right border. The subject is instructed to make a mark along the line to represent the intensity of right leg pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-randomized ACADIA®</title>
            <description>Non-randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
          </group>
          <group group_id="O2">
            <title>Randomized ACADIA®</title>
            <description>Randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
          </group>
          <group group_id="O3">
            <title>Randomized Instrumented PLF</title>
            <description>Randomized control surgical treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Visual Analog Scale (VAS) Right Leg Pain</title>
          <description>The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with &quot;no pain&quot; on the left border and &quot;as severe as it could be&quot; on the right border. The subject is instructed to make a mark along the line to represent the intensity of right leg pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="28.11"/>
                    <measurement group_id="O2" value="13.2" spread="24.97"/>
                    <measurement group_id="O3" value="22.5" spread="30.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Visual Analog Scale (VAS) Left Leg Pain</title>
        <description>The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with &quot;no pain&quot; on the left border and &quot;as severe as it could be&quot; on the right border. The subject is instructed to make a mark along the line to represent the intensity of left leg pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-randomized ACADIA®</title>
            <description>Non-randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
          </group>
          <group group_id="O2">
            <title>Randomized ACADIA®</title>
            <description>Randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
          </group>
          <group group_id="O3">
            <title>Randomized Instrumented PLF</title>
            <description>Randomized control surgical treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Visual Analog Scale (VAS) Left Leg Pain</title>
          <description>The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with &quot;no pain&quot; on the left border and &quot;as severe as it could be&quot; on the right border. The subject is instructed to make a mark along the line to represent the intensity of left leg pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="29.72"/>
                    <measurement group_id="O2" value="12.2" spread="24.25"/>
                    <measurement group_id="O3" value="16.9" spread="26.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Visual Analog Scale (VAS) Back Pain</title>
        <description>The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with &quot;no pain&quot; on the left border and &quot;as severe as it could be&quot; on the right border. The subject is instructed to make a mark along the line to represent the intensity of back pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-randomized ACADIA®</title>
            <description>Non-randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
          </group>
          <group group_id="O2">
            <title>Randomized ACADIA®</title>
            <description>Randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
          </group>
          <group group_id="O3">
            <title>Randomized Instrumented PLF</title>
            <description>Randomized control surgical treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Visual Analog Scale (VAS) Back Pain</title>
          <description>The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with &quot;no pain&quot; on the left border and &quot;as severe as it could be&quot; on the right border. The subject is instructed to make a mark along the line to represent the intensity of back pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" spread="30.23"/>
                    <measurement group_id="O2" value="18.8" spread="25.24"/>
                    <measurement group_id="O3" value="23.9" spread="26.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Change of at Least 15 Points in Pain/Disability Using the Oswestry Disability Index (ODI) Score at 24 Months Compared With the Score at Baseline</title>
        <description>The Oswestry Disability Index (ODI) is a commonly used outcome-measure questionnaire for low back pain in a hospital setting. It is a self-administered questionnaire divided into ten sections designed to assess limitations of various activities of daily living. Each section is scored on a 0-5 scale, 5 representing the greatest disability. The scores for all questions answered are summed, then multiplied by two to obtain the index (range 0 to 100). Zero is equated with no disability and 100 is the maximum disability possible.</description>
        <time_frame>24 months</time_frame>
        <population>Six Non-randomized ACADIA®, 37 Randomized ACADIA® and 23 Randomized instrumented PLF did not complete the 24 month visit and thus were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-randomized ACADIA®</title>
            <description>Non-randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
          </group>
          <group group_id="O2">
            <title>Randomized ACADIA®</title>
            <description>Randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
          </group>
          <group group_id="O3">
            <title>Randomized Instrumented PLF</title>
            <description>Randomized control surgical treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Change of at Least 15 Points in Pain/Disability Using the Oswestry Disability Index (ODI) Score at 24 Months Compared With the Score at Baseline</title>
          <description>The Oswestry Disability Index (ODI) is a commonly used outcome-measure questionnaire for low back pain in a hospital setting. It is a self-administered questionnaire divided into ten sections designed to assess limitations of various activities of daily living. Each section is scored on a 0-5 scale, 5 representing the greatest disability. The scores for all questions answered are summed, then multiplied by two to obtain the index (range 0 to 100). Zero is equated with no disability and 100 is the maximum disability possible.</description>
          <population>Six Non-randomized ACADIA®, 37 Randomized ACADIA® and 23 Randomized instrumented PLF did not complete the 24 month visit and thus were not analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="151"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>The Total Number of Participants at Risk for the &quot;Randomized ACADIA&quot; Arm/Group is not consistent with numbers provided in the Participant Flow module. The discrepancy is due to one patient being randomized to ACADIA but not receiving the ACADIA treatment. This patient is included in the intent-to-treat population for efficacy analyses. It is not possible to make any changes to data including Adverse Event Terms as the study is closed and all analysis is complete.</desc>
      <group_list>
        <group group_id="E1">
          <title>Non-randomized ACADIA®</title>
          <description>Non-randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
        </group>
        <group group_id="E2">
          <title>Randomized ACADIA®</title>
          <description>Randomized investigational surgical treatment using the ACADIA Facet Replacement system for the treatment of lumbar spinal stenosis</description>
        </group>
        <group group_id="E3">
          <title>Randomized Instrumented PLF</title>
          <description>Randomized control surgical treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Radiographic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Metal Allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Deep Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Infection - Superficial Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain-Neck and/or Upper Extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain-Back and Lower Extremities</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain Lower Extremities</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain - Hip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dural Tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Neurological Focal Lumbar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urogenital</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Wound Issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgery - Adjacent Level</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Surgery - Index Level</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Surgery - Other (Non-Lumbar)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Surgery - Other Lumbar</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="213" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Spinous Process Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dural Tear</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Radiographic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Pseudoarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Metal Allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Superficial Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain-Neck and/or Upper Extremity</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain-Back and Lower Extremities</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain - Back and Hip</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain Lower Extremities</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain - Hip</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain-Back and Lower Extremities with Dysesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain-Back with Dysesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Pain Lower Extremities with Dysesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysesthesia - Upper Extremities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dysesthesia - Lower Extremities</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Neurological Systemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Dysesthesia - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Paresthesia - Upper Extremities</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Paresthesia - Lower Extremities</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Paresthesia - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Neurological Focal Lumbar</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Neurolgical Focal Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Peripheral Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urogenital</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Wound Issue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgery - Adjacent Level</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Surgery-Index Level</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Surgery - Other (Non-Lumbar)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Surgery - Other Lumbar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>To prevent premature disclosure of trade secrets or other confidential information, Investigator agrees not to present, publish, or disclose study results or information about the investigational device without the express written consent of the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Affairs</name_or_title>
      <organization>Globus Medical</organization>
      <phone>610-930-1800</phone>
      <email>jmyer@globusmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

